research 1457 CellutomeTM epidermal harvesting system and in vivo reflectance confocal microscopy as a novel wound healing assessment protocol
The new protocol using Cellutome™ and RCM safely assesses wound healing in detail.
Search
for
Sort by
Research
360-390 / 1000+ results 
research Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data
Tralokinumab for atopic dermatitis may cause side effects like dizziness, headache, nausea, hair loss, and acne.
research Role of EZH2 in Uterine Gland Development
EZH2 is crucial for uterine gland development and female fertility.
research Conjoint analysis of methylation, transcriptomic, and proteomic profiles in pemphigus vulgaris
Changes in genes FGA, VWF, and ACTG1 may contribute to pemphigus vulgaris.
research HuR ablation destabilizes Foxp3 mRNA and impairs regulatory T cell function, contributing to an autoimmune phenotype
HuR is essential for Treg function and preventing autoimmunity.
research Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study
Tamsulosin with Serenoa repens is as effective as with 5-alpha-reductase inhibitors but causes fewer side effects.
research Tralokinumab as a therapeutic option for patients with concurrent atopic dermatitis and alopecia areata
research 820 Filling Injection of Platelet-rich Plasma Gel as A New Method to Treat En Coup de Sabre Scleroderma
Platelet-rich Plasma Gel may help treat en coup de sabre scleroderma, improving symptoms and skin quality with minimal side effects.
research Recombinant Thrombomodulin Used to Successfully Treat Cronkhite-Canada Syndrome with Disseminated Intravascular Coagulation due to Sepsis in a Compromised Patient
Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.
research Teriflunomide in multiple sclerosis: an update
Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
research Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review
Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
research Alopecia areata in 2 patients treated with dupilumab: New onset and worsening
Dupilumab for atopic dermatitis may cause new or worsen existing alopecia areata.
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
research Erythroid Differentiation Regulator 1 as a Novel Biomarker for Hair Loss Disorders
Erdr1 could be a new marker for diagnosing hair loss.
research EVIDÊNCIAS ACERCA DO USO DO ANTICORPO MONOCLONAL TOCILIZUMABE COMO TERAPÊUTICA PARA COVID-19
Tocilizumab might be an effective treatment for COVID-19.
research LB922 CyTOF immune profiling uncovers sex- and race-specific differences and cellular biomarkers for biologic response in Hidradenitis suppurativa
Sex and race affect immune responses and treatment outcomes in Hidradenitis suppurativa.
research Dupilumab and alopecia: A Janus effect
Dupilumab can both heal and cause hair loss.
research BH17 Bridging the gap: identifying dual-targeting therapies for patients with alopecia areata and coexisting immune-mediated inflammatory diseases
Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Managing Skin Ageing as a Modifiable Disorder—The Clinical Application of Nourella® Dual Approach Comprising a Nano-Encapsulated Retinoid, Retilex-A® and a Skin Proteoglycan Replacement Therapy, Vercilex®
Nourella® effectively improves skin thickness and elasticity, reversing aging signs.
research Brimonidine Beyond a Single Specialty: Pharmacological Profile, Dermatologic Applications, and Advances in Drug Delivery Systems
Brimonidine is effective for reducing facial redness in skin conditions and has potential for broader dermatological uses.
research Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research P368 Rare skin disorders in IBD patients treated with anti-TNFs
Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.
research Rational Design and Synthesis of 4-((1R,2R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a Novel, Nonsteroidal Androgen Receptor Antagonist Devoid of Phototoxicity for Dermatological Indications
PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
research 519 Phase I/IIa clinical trial for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes
The gene therapy showed significant wound healing and was safe for treating severe RDEB.
research Provenge is Talk of GU Malignancies Congress
Provenge extends prostate cancer survival by about 4 months.
research Successful Dupilumab Administration in Adolescent with Alopecia Areata and Atopic Dermatitis: Clinical Case
Dupilumab helped an 11-year-old boy regrow hair and reduce skin rashes.
research Cell Membrane-Camouflaged Nanoparticles Mediated Nucleic Acids Delivery
Cell membrane-coated nanoparticles could improve gene therapy by enhancing delivery and targeting of nucleic acids.
research New product intros (finasteride/tadalafil (new combination); sutimlimab; human SARS-CoV-2 recombinant nanoparticle vaccine, adjuvanted with AS03; bupropion hydrochloride/dextromethorphan hydrobromide (new combination))
research Table 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.